We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation
Read MoreHide Full Article
Key Takeaways
STXS partners with CardioFocus to create a robotic PFA system for cardiac arrhythmia treatment.
The collaboration merges robotic precision with advanced PFA technology for safer, faster ablations.
STXS gains access to the expanding PFA market, enhancing its robotics portfolio and growth potential.
Stereotaxis (STXS - Free Report) recently partnered with CardioFocus to develop the first robotic Pulsed Field Ablation (PFA) system for treating cardiac arrhythmias. The collaboration brings together Stereotaxis’ robotic precision and CardioFocus’s advanced PFA technology to accelerate the path toward clinical use and commercialization.
The partnership is expected to benefit both companies by combining proven strengths in robotics and ablation science. It positions them to deliver safer, more efficient treatment options in electrophysiology while expanding their presence in the growing cardiac care market.
Likely Trend of STXS Stock Following the News
Following the announcement, the company's shares traded flat at yesterday’s closing. In the year-to-date period, shares have gained 34.7% against the industry’s 10.8% decline. The S&P 500 has gained 12.2% in the same time frame.
The partnership with CardioFocus positions Stereotaxis to expand its footprint in the high-growth cardiac ablation market by integrating advanced PFA technology into its robotic platform. This collaboration enhances STXS’ product portfolio and opens potential new revenue streams from next-generation electrophysiology solutions, strengthening its competitive edge and long-term growth potential in minimally invasive cardiac care.
STXS currently has a market capitalization of $279.6 million. In the last reported quarter, STXS delivered an earnings surprise of 28.6%.
Image Source: Zacks Investment Research
More on the Collaboration
Stereotaxis and CardioFocus have entered into a collaboration agreement to advance robotic PFA technology toward commercialization, a move that could redefine treatment for cardiac arrhythmias. The partnership integrates CardioFocus’s CE-marked Centauri PFA System, already used in over 9,000 patients across Europe, with Stereotaxis’ MAGiC robotic cardiac ablation catheter powered by its Robotic Magnetic Navigation (RMN) platform.
Together, these technologies aim to deliver the first-ever robotic PFA solution, combining the precision, stability and safety of robotics with the efficiency and durable lesion quality of CardioFocus’s patented PFA waveform. The companies have already completed extensive bench and preclinical testing, showing safe and effective lesion delivery in ventricular tissue.
The collaboration agreement supports the transition to human clinical trials and facilitates the regulatory and commercial alignment of the joint solution. Both firms are working closely to accelerate approval timelines and ensure compatibility between the MAGiC catheter and the Centauri PFA system. Stereotaxis’ RMN technology has already been used in over 150,000 cardiac ablation procedures globally and supported by more than 500 publications, a solid foundation that enhances the credibility and readiness of this next-generation robotic PFA platform.
For both companies, this partnership brings strategic and financial upside. Stereotaxis gains access to the rapidly expanding PFA segment, boosting its innovation pipeline and strengthening its position in electrophysiology robotics, while CardioFocus benefits from Stereotaxis’ global reach and robotic precision to enhance clinical outcomes and expand adoption of its PFA technology. Together, they aim to set a new benchmark in cardiac ablation, improving patient care and creating fresh commercial opportunities in the global cardiac treatment landscape.
Favorable Industry Prospects for STXS
Per a report by Grand View Research, the global pulsed field ablation market size was estimated at $913.1 million in 2024 and is projected to expand at a CAGR of 33.1% from 2025 to 2030.
The rapid growth of the global PFA market is driven by the rising prevalence of atrial fibrillation, the increasing adoption of minimally invasive cardiac procedures and strong clinical evidence supporting PFA’s safety and efficiency over traditional thermal ablation methods.
Masimo shares have lost 10.4% so far this year compared with the industry’s 7.4% decline. Estimates for the company’s 2025 earnings per share have increased 1.3% to $5.30 in the past 30 days.
MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Merit Medical’s 2025 earnings per share have increased 0.8% to $3.63 in the past 60 days. Shares of the company have lost 13.8% so far this year against the industry’s 1.1% growth.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.92%. In the last reported quarter, it delivered an earnings surprise of 17.44%.
Estimates for West Pharmaceutical’s 2025 earnings per share have increased 1.2% to $6.74 in the past 60 days. Shares of the company have lost 18.2% so far this year against the industry’s 1% growth.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.81%. In the last reported quarter, it delivered an earnings surprise of 21.85%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation
Key Takeaways
Stereotaxis (STXS - Free Report) recently partnered with CardioFocus to develop the first robotic Pulsed Field Ablation (PFA) system for treating cardiac arrhythmias. The collaboration brings together Stereotaxis’ robotic precision and CardioFocus’s advanced PFA technology to accelerate the path toward clinical use and commercialization.
The partnership is expected to benefit both companies by combining proven strengths in robotics and ablation science. It positions them to deliver safer, more efficient treatment options in electrophysiology while expanding their presence in the growing cardiac care market.
Likely Trend of STXS Stock Following the News
Following the announcement, the company's shares traded flat at yesterday’s closing. In the year-to-date period, shares have gained 34.7% against the industry’s 10.8% decline. The S&P 500 has gained 12.2% in the same time frame.
The partnership with CardioFocus positions Stereotaxis to expand its footprint in the high-growth cardiac ablation market by integrating advanced PFA technology into its robotic platform. This collaboration enhances STXS’ product portfolio and opens potential new revenue streams from next-generation electrophysiology solutions, strengthening its competitive edge and long-term growth potential in minimally invasive cardiac care.
STXS currently has a market capitalization of $279.6 million. In the last reported quarter, STXS delivered an earnings surprise of 28.6%.
Image Source: Zacks Investment Research
More on the Collaboration
Stereotaxis and CardioFocus have entered into a collaboration agreement to advance robotic PFA technology toward commercialization, a move that could redefine treatment for cardiac arrhythmias. The partnership integrates CardioFocus’s CE-marked Centauri PFA System, already used in over 9,000 patients across Europe, with Stereotaxis’ MAGiC robotic cardiac ablation catheter powered by its Robotic Magnetic Navigation (RMN) platform.
Together, these technologies aim to deliver the first-ever robotic PFA solution, combining the precision, stability and safety of robotics with the efficiency and durable lesion quality of CardioFocus’s patented PFA waveform. The companies have already completed extensive bench and preclinical testing, showing safe and effective lesion delivery in ventricular tissue.
The collaboration agreement supports the transition to human clinical trials and facilitates the regulatory and commercial alignment of the joint solution. Both firms are working closely to accelerate approval timelines and ensure compatibility between the MAGiC catheter and the Centauri PFA system. Stereotaxis’ RMN technology has already been used in over 150,000 cardiac ablation procedures globally and supported by more than 500 publications, a solid foundation that enhances the credibility and readiness of this next-generation robotic PFA platform.
For both companies, this partnership brings strategic and financial upside. Stereotaxis gains access to the rapidly expanding PFA segment, boosting its innovation pipeline and strengthening its position in electrophysiology robotics, while CardioFocus benefits from Stereotaxis’ global reach and robotic precision to enhance clinical outcomes and expand adoption of its PFA technology. Together, they aim to set a new benchmark in cardiac ablation, improving patient care and creating fresh commercial opportunities in the global cardiac treatment landscape.
Favorable Industry Prospects for STXS
Per a report by Grand View Research, the global pulsed field ablation market size was estimated at $913.1 million in 2024 and is projected to expand at a CAGR of 33.1% from 2025 to 2030.
The rapid growth of the global PFA market is driven by the rising prevalence of atrial fibrillation, the increasing adoption of minimally invasive cardiac procedures and strong clinical evidence supporting PFA’s safety and efficiency over traditional thermal ablation methods.
STXS’s Zacks Rank & Key Picks
Currently, STXS carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Merit Medical System (MMSI - Free Report) and West Pharmaceutical Services (WST - Free Report) . Each stock presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Masimo shares have lost 10.4% so far this year compared with the industry’s 7.4% decline. Estimates for the company’s 2025 earnings per share have increased 1.3% to $5.30 in the past 30 days.
MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. In the last reported quarter, it posted an earnings surprise of 8.1%.
Estimates for Merit Medical’s 2025 earnings per share have increased 0.8% to $3.63 in the past 60 days. Shares of the company have lost 13.8% so far this year against the industry’s 1.1% growth.
MMSI’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.92%. In the last reported quarter, it delivered an earnings surprise of 17.44%.
Estimates for West Pharmaceutical’s 2025 earnings per share have increased 1.2% to $6.74 in the past 60 days. Shares of the company have lost 18.2% so far this year against the industry’s 1% growth.
WST’s earnings beat estimates in each of the trailing four quarters, the average surprise being 16.81%. In the last reported quarter, it delivered an earnings surprise of 21.85%.